Inhibitory effect of somatostatin on prostaglandin E2 synthesis by primary neonatal rat glial cells

Regulatory Peptides

Volumn 150, Issue 1-3, 2008, Pages 21-25

  Dror, Naama ^a   Tveria, Liat ^a   Meniv, Inbal ^a   Ben Shmuel, Sarit ^a   Filipovich, Talia ^a   Fleisher Berkovich, Sigal ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Brain inflammation; Lipopolysaccharide; Prostaglandin E2; Somatostatin

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FORSKOLIN; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; SOMATOSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEEDBACK SYSTEM; GLIA CELL; INFLAMMATION; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SYNTHESIS;

AMIDES; ANIMALS; ANIMALS, NEWBORN; BRAIN; CELLS, CULTURED; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALITIS; FORSKOLIN; HORMONE ANTAGONISTS; INDOLES; ISOQUINOLINES; LIPOPOLYSACCHARIDES; NEUROGLIA; NITROBENZENES; OCTREOTIDE; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SULFONAMIDES;

RATTUS;

EID: 51249119410     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.06.005     Document Type: Article

References (34)

1. McGeer P.L., and McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21 (1995) 195-218
2. A.H. Moore, M.K. O'Banion. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Del Rev 54 1627-56.
3. Akiyama H., Arai T., Kondo H., Tanno E., Haga C., and Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord 14 (2000) 47-53
4. Pasinetti G.M., and Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87 (1998) 319-324
5. Kitamura Y., Shimohamas S., and Koike H. Increased expression of cyclooxygenases and peroxisome proliferators activated receptor gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 254 (1999) 582-586
6. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Lui B., and Hong J.S. Regional difference in susceptibility to lipopolysaccaride-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20 (2000) 6309-6316
7. I'nt Veld B.A., Ruitenberg A., and Hofman A. Nonsteroidal anti inflammatory drug and the risk of Alzheimer's disease. N Eng J Med 345 (2001) 1515-1521
8. 2 levels in patients with probable AD. Neurology 53 (1999) 1495-1498
9. Reichlin S. Somatostatin I. New Eng J Med 309 (1983) 1495-1501
10. Bennett G.W., Ballard T.M., Watson C.D., and Fone K.C. Effect of neuropeptides on cognitive function. Exp Gerontol 32 (1997) 451-469
11. Davies P., Katzman R., and Terry R.D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer's senile dementia. Nature 288 (1980) 279-280
12. Karalis K., Mastorakos G., Sano H., Wilder R.L., and Chrousos G.P. Somatostatin may participate in the antiinflammatory action of glucocorticoids. Endocrinology 136 (1995) 4133-4138
13. Feindt J., Becker I., Blomer U., Hugo H.H., Mehdorn H.M., Krisch B., et al. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem 65 (1995) 1997-2005
14. Feindt J., Schmidt A., and Mentlein R. Receptors and effects of the inhibitory neuropeptide somatostatin in microglial cells. Brain Res Mol Brain Res 60 (1998) 228-233
15. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 134 (2005) 525-538
16. Levant A., Levy E., Argaman M., and Fleisher-Berkovich S. Kinins and neuroinflammation: dual effect on prostaglandin synthesis. Eur J Pharmacol 546 (2006) 197-200
17. Brenner T., Boneh A., Shohami E., Abramsky O., and Weidenfeld J. Glucocorticoid regulation of eicosanoid production by glial cells under basal and stimulated conditions. J Neuroimmunol 40 (1992) 273-279
18. Bhathena S.J., Louie J., Schechter G.P., Redman R.S., Wahl L., and Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 30 (1981) 127-131
19. Murphy W.J. Effects of growth hormone, insulin-like growth factor-I and somatostatin on immune function and development. In: Marsh J.A., and Kendall M.D. (Eds). The Physiology of Immunity (1996), CRC Press, Boca Raton 197-209
20. Peluso G., Petillo O., Melone MAB Mazzarella G., Ranieri M., and Tajana G.F. Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides 30 (1996) 443-451
21. Paran D., and Paran H. Somatostatin analogs in rheumatoid arthritis and other inflammatory and immune-mediated conditions. Curr Opin Investig Drugs 4 (2003) 578-582
22. Grimaldi M., Florio T., and Schettini G. Somatostatin inhibits IL-6 release from rat cortical type I astrocytes via the inhibition of adenylyl cyclase. Biochem Biophysic Res Com 235 (1997) 242-248
23. 2 in rat astrocyte cultures: modulatory effect of neuropeptides. Endocrinology 124 (1989) 3125-3127
24. Patel Y.C., Panetta R., Escher E., Greenwood M., and Srikant C.B. Expression of multiple somatostatin receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective receptor subtype. J Biol Chem 269 (1994) 1506-1509
25. Csaba Z., and Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 35 (2001) 1-23
26. Minghetti L., Polazzi E., Nicolini A., and Creminon C. Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non steroidal anti-inflammatory drugs. Eur J Neurosci 9 (1997) 934-940
27. Nickels D., Schwab N., and Poth M. Effects of somatostatin and captopril on glomerular prostaglandin E2 production in normal and diabetic rats. Prostaglandins 46 (1993) 61-73
28. Smelt A.H., Meinders A.E., Hoekman K., Noort W.A., and Keirse M.J. Secretory diarrhea in villous adenoma of rectum: effect of treatment with somatostatin and indomethacin. Prostaglandins 43 (1992) 567-572
29. Marbach P., Briner U., Lemaire M., Schweitzer A., and Terasaki T. From somatostatin to sandostatin: pharmacodynamics and pharmacokinetics. Metabolism 41 (1992) 7-10
30. Berelowitz M., Dudlak D., and Frohman L.A. Release of somatostatin-like immunoreactivity from incubated rat hypothalamus and cerebral cortex. J Clin Invest 69 (1981) 1293-1301
31. Jeohn G.H., Kong L.Y., Wilson B., Hudson P., and Hong J.S. Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J Neuroimmunol 85 (1998) 1-10
32. Dixon D.W., Mattiace L.A., Kure K., Hutchins K., Lyman X., and Brosnan C.F. Microglia in human disease, with an emphasis on acquired immune deficiency syndrome. Lab Invest 64 (1991) 135-156
33. Krantic S. Peptides as regulators of the immune system: emphasis on somatostatin. Peptides 21 (2000) 1941-1964
34. Streit W.J., Graeber M.B., and Kreutzberg G.W. Functional plasticity of microglia: a review. Glia 1 (1988) 301-307